Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on November 24, 2025, and filed on November 25, 2025. The filing details a share repurchase executed through BNP Paribas SA as part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing focuses exclusively on share repurchase activity and capital structure updates. It does not contain revenue, profit, cash flow, margin, or debt metrics.
- Shares Purchased (Nov 24, 2025): 170,000 ordinary shares.
- Price Range: Lowest 1,775.50p; Highest 1,793.50p.
- Volume-Weighted Average Price (VWAP): 1,784.93p.
- Total Buyback Since Sept 30, 2025: 10,308,000 ordinary shares.
- Treasury Shares Held: 235,772,844 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,079,659,083 ordinary shares.
- Treasury Voting Rights: 5.78% of total voting rights.
Material Changes
Following the November 24 transaction, the company's treasury shareholding increased to 235,772,844 shares. Consequently, the percentage of voting rights attributable to treasury shares is confirmed at 5.78%. The total number of voting rights remains 4,079,659,083. No other material financial changes are reported in this filing.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's 2024 Annual Report on Form 20-F and Q3 2025 Results.
Investor Verification Checklist
- Verify the total cumulative buyback volume against the September 30, 2025, programme announcement to assess remaining capacity.
- Confirm the 5.78% treasury voting rights percentage for compliance with FCA Disclosure Guidance and Transparency Rules (DTR 5.5.1R).
- Review the detailed trade schedule to ensure execution prices remained within the agreed non-discretionary agreement parameters.
- Check the updated share count (4,079,659,083) for accurate EPS and dividend per share calculations in future reports.